Related Experiment Video

Updated: Aug 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Immune-based novel therapies for chronic hepatitis C virus infection

Kazuhiro Kakimi1

  • 1Fourth Department of Internal medicine, Tokyo Medical University, Nishi-Shinjuku 6-1, Shinjuku-ku, Tokyo 160-0023, Japan. kakimi@tokyo-med.ac.jp

Human Cell
|May 19, 2004
PubMed

Insights

Hepatitis C virus (HCV) infection impacts millions globally. Novel immune-based therapies, particularly those inducing interferon-gamma, show promise for controlling chronic HCV infection where current treatments are limited.

Area of Science:

  • Immunology
  • Virology
  • Hepatology

Background:

  • Hepatitis C virus (HCV) infection is a significant global health issue affecting 200 million people.
  • Current treatments like interferon-alpha (IFN-alpha) and Ribavirin have limited efficacy, with only a subset of patients responding.
  • The host immune response plays a critical role in the pathogenesis and outcome of HCV infection.

Purpose of the Study:

  • To review novel immune-based therapeutic strategies for HCV infection.
  • To present evidence supporting the use of these therapies in chronic hepatitis C patients.

Main Methods:

  • Review of existing scientific literature on HCV immune response and novel therapies.
  • Analysis of evidence linking intrahepatic T cell responses and interferon-gamma (IFN-gamma) to viral control.

Main Results:

  • A vigorous intrahepatic CD4+ and CD8+ T cell response is associated with acute HCV control.
  • IFN-gamma presence in the liver correlates with viral clearance or control in chimpanzees.
  • Therapeutic induction of intrahepatic IFN-gamma via adoptive immunotherapy is a potential strategy.

Conclusions:

  • Immune-based therapies offer a promising new avenue for treating chronic HCV infection.
  • Harnessing the host's immune system, specifically through IFN-gamma induction, could lead to effective viral control.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...